APA (7th ed.) Citation

Kim, S., Cayre, A., Jary, M., Jacquin, M., Arbez-Gindre, F., Fein, F., . . . Borg, C. (2016). Complete Response to Aflibercept-FOLFIRI in One Patient With Colorectal Cancer Refractory to Bevacizumab-FOLFOX: A Possible Autocrine Vascular Endothelial Growth Factor Receptor 2–Related Mechanism. Clinical colorectal cancer, 15(4), e229-e234. https://doi.org/10.1016/j.clcc.2016.07.015

Chicago Style (17th ed.) Citation

Kim, Stefano, Anne Cayre, Marine Jary, Marion Jacquin, Francine Arbez-Gindre, Francine Fein, Zaher Lakkis, Thierry Nguyen, and Christophe Borg. "Complete Response to Aflibercept-FOLFIRI in One Patient With Colorectal Cancer Refractory to Bevacizumab-FOLFOX: A Possible Autocrine Vascular Endothelial Growth Factor Receptor 2–Related Mechanism." Clinical Colorectal Cancer 15, no. 4 (2016): e229-e234. https://doi.org/10.1016/j.clcc.2016.07.015.

MLA (9th ed.) Citation

Kim, Stefano, et al. "Complete Response to Aflibercept-FOLFIRI in One Patient With Colorectal Cancer Refractory to Bevacizumab-FOLFOX: A Possible Autocrine Vascular Endothelial Growth Factor Receptor 2–Related Mechanism." Clinical Colorectal Cancer, vol. 15, no. 4, 2016, pp. e229-e234, https://doi.org/10.1016/j.clcc.2016.07.015.